PMID- 32566585
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220830
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 8
IP  - 10
DP  - 2020 May
TI  - Efficacy and safety of sofosbuvir-containing regimens in patients with chronic 
      hepatitis C virus infection after liver transplantation: a meta-analysis.
PG  - 648
LID - 10.21037/atm-20-3074 [doi]
LID - 648
AB  - BACKGROUND: This meta-analysis evaluated the efficacy and safety of a sofosbuvir 
      (SOF)-containing regimen in patients with hepatitis C virus (HCV) infection after 
      liver transplantation (LT). METHODS: We performed a systematic search for 
      relevant published data on the PubMed, EMBASE, and Cochrane Library databases. 
      Studies that evaluated any regimen in which SOF was used to treat patients with 
      HCV infection after LT and reported the sustained virologic response 12 weeks 
      (SVR12) after therapy were included. RESULTS: A total of 12 studies, involving 
      892 patients, were included in this analysis. The pooled estimate of SVR12 
      (sustained virologic response 12 weeks) was 88.1%. Subgroup analysis showed that 
      patients who received SOF plus other DAAs had higher SVR12 than those treated 
      with SOF plus ribavirin or peg-IFN. The pooled incidence of any adverse events 
      (AEs) was 73.7%. CONCLUSIONS: The results of this study showed that the treatment 
      response of SOF-containing regimens in patients with HCV infection after LT was 
      satisfactory. However, more attention needs to be paid to the high rate of AEs 
      associated with such regimens.
CI  - 2020 Annals of Translational Medicine. All rights reserved.
FAU - Fu, Hua
AU  - Fu H
AD  - Hospital and Institute of Hepatobiliary Surgery, Chinese PLA General Hospital, 
      Chinese PLA Medical School, Beijing, China.
AD  - Department of Hepatobiliary Surgery, Affiliated Hospital of Chengde Medical 
      University, Chengde, China.
FAU - Dong, Jiahong
AU  - Dong J
AD  - Hospital and Institute of Hepatobiliary Surgery, Chinese PLA General Hospital, 
      Chinese PLA Medical School, Beijing, China.
AD  - Center of Hepatopancreatobiliary Diseases, Beijing Tsinghua Changgung Hospital, 
      Tsinghua University, Beijing, China.
FAU - Sun, Zhide
AU  - Sun Z
AD  - Department of Hepatobiliary Surgery, Affiliated Hospital of Chengde Medical 
      University, Chengde, China.
FAU - Zhang, Xuejun
AU  - Zhang X
AD  - Department of Hepatobiliary Surgery, Affiliated Hospital of Chengde Medical 
      University, Chengde, China.
FAU - Yu, Aijun
AU  - Yu A
AD  - Department of Hepatobiliary Surgery, Affiliated Hospital of Chengde Medical 
      University, Chengde, China.
FAU - Chen, Guoli
AU  - Chen G
AD  - Department of Hepatobiliary Surgery, Affiliated Hospital of Chengde Medical 
      University, Chengde, China.
FAU - Li, Wei
AU  - Li W
AD  - Department of Hepatobiliary Surgery, Affiliated Hospital of Chengde Medical 
      University, Chengde, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC7290620
OTO - NOTNLM
OT  - Sofosbuvir
OT  - hepatitis C virus infection (HCV infection)
OT  - liver transplantation (LT)
OT  - meta-analysis
OT  - sustained virologic response 12 weeks (SVR12)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/atm-20-3074). The authors have no 
      conflicts of interest to declare.
EDAT- 2020/06/23 06:00
MHDA- 2020/06/23 06:01
PMCR- 2020/05/01
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/06/23 06:01 [medline]
PHST- 2020/05/01 00:00 [pmc-release]
AID - atm-08-10-648 [pii]
AID - 10.21037/atm-20-3074 [doi]
PST - ppublish
SO  - Ann Transl Med. 2020 May;8(10):648. doi: 10.21037/atm-20-3074.